本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP iPSCs derived from type O female blood and started offering as an off-the-shelf product. It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response in patients, however, there has recently been an increased demand for type O female blood-derived iPSCs. Type O female blood-derived iPSCs have multiple merits including the low immunoreaction risk from ABO blood type and Y chromosome-derived proteins. With the offering of these off-the-shelf, low immunoreaction risk iPSCs, I Peace's iPSC offerings have been enriched to serve a wider variety of cell therapy developers and pharmaceutical companies. Advantages of type O blood-derived iPSCs Because of the absence of A or B antigens, type O blood donors are considered "universal donors" for blood transfusions. Likewise, iPS cells derived from type B lymphocytes demonstrate greater universal compatibility, simplifying the logistics of matching donor cells to recipients. Advantages of female donor-derived iPSCs Male donors contribute a Y chromosome, which is smaller, contains fewer genes, and is prone to specific genetic instabilities during extended culture or reprogramming processes. This could impact the quality or safety of iPSC-derived therapies. Female donors avoid this risk, potentially leading to greater genetic stability in the iPSC line. Proteins encoded by the Y chromosome may also act as antigens and trigger immune responses in female recipients. Female-derived cells lack these antigens, making them more universally applicable. Furthermore, female-derived iPSCs may be preferred for studies or therapies related to female-specific diseases or conditions, as they inherently reflect female physiology. I Peace will continue to provide iPSCs and cell-related CDMO services to more companies and institutions to bring iPSC-derived therapies closer to everyone. I Peace, inc. I Peace, inc. provides GMP iPS cells globally and is an entrusted manufacturing service provider of various medical grade cells. The company was founded in 2015 by Koji Tanabe, a graduate of Professor Shinya Yamanaka's laboratory at Kyoto University, and the second author of the paper that reported the successful establishment of the world's first human iPS cell line. Tanabe has been involved in iPS cell research since the early days of its development and is working daily on innovative technical developments to make iPS cells accessible to everyone through I Peace, inc. Our unique technology enables us to produce multiple donor-derived iPS cells in parallel without contamination concerns and to provide scalable iPS cell manufacturing at a reasonable price. We are also promoting the production of iPS cells for individuals so that everyone in the world can prepare for the future by preserving their own iPS cells. We support drug discovery and cell medicine development by providing iPS cells and other cell products that meet PMDA and FDA standards to pharmaceutical and cell medicine development companies so that cell medicine can become available to patients as soon as possible. Our ultimate goal is to enhance the prevalence of regenerative medicine by establishing iPS cell banking services for individuals and making iPS cells accessible to other development companies working with this incredible technology. I Peace, Inc.Founder & CEO: Koji TanabeEstablished: 2015Headquarters: Palo Alto, California, U.S.A.Subsidiary in Japan: I Peace, Ltd., KyotoiPS cell manufacturing base: Peace Engine Kyoto, KyotoWebsite: https://ipeace.com/en/
SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- The KOREA INNOVATION FOUNDATION (INNOPOLIS) participated in Asia's largest deep-tech event 'SWITCH 2024' held at Marina Bay Sands in Singapore from the 27th to the 30th and supported the global expansion of 10 excellent startups from South Korea. KOREA INNOVATION FOUNDATION (INNOPOLIS) attended SWITCH 2024 with 10 Korean startups. Attending to SWITCH 2024 under INNOPOLIS Pavilion, 10 excellent Korea startups has exhibited their newest technologies in various fields: artificial intelligence (AI) and eco-friendly technology, biotechnology, robotic, etc. and to increase global awareness and strengthen cooperation with overseas markets. Additionally, INNOPOLIS Pavilion also attended SLINGSHOT pitching competition - the main event of SWITCH 2024 and a global startup competition and got qualified into the final round. AgosVision, which develops a wide-field 3D vision sensor, drew attention by being selected as a TOP 50 at SLINGSHOT 2024. During SWITCH period, INNOPOLIS organized and operated various programs during SWITCH, such as the Global Demo Day, and AIMX Summit 2024, to enable the 10 startups to showcase their latest technologies and product excellence to the global market. First, at the INNOPOLIS Global Demo Day, they introduced the innovative technologies and products of startups to major investors and buyers in Southeast Asia and expanded global cooperation opportunities through B2B networking. At the AIMX Summit 2024, INNOPOLIS held a Korean session with the theme of 'AI Briefing and Update: South Korea' to introduce the AI technology trends and industry status of the special zone, and a total of six countries including Vietnam, the UK, Japan, Europe, China, and Korea participated to share the latest AI trends. At the INNOPOLIS Global Demo Day, Edward Tay - SGTech Honoray Treasurer of SG Tech Singapore, also known as SWITCH Ambassador, has presented on the global market entry and cooperation network building of Korean companies, said, "Many VCs and buyers in Southeast Asia, including Singapore, are showing great interest in the innovative technologies and products of Korean startups". And through this event, Korean startups has pitched and had business networking with global VCs from Singapore, Indonesia, Malaysia and attracted significant interest with their technologies, which is a milestone of for their future global expansion.
SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- The KOREA INNOVATION FOUNDATION (INNOPOLIS) – an R&D Innovation Cluster Of The Republic Of Korea has at participated in SWITCH 2024 (Singapore) – the largest tech event in Southeast Asia. KOREA INNOVATION FOUNDATION (INNOPOLIS) hosted Global Demoday and spoke at AIMX Summit during SWITCH 2024 SINGAPORE. With the purpose of incubating and supporting global expansion for R&D startups in South Korea, INNOPOLIS had executed a long-run accelerating program to leverage their IR capability for Korean companies and selected 10 excellent Korean startups and supported them to have opportunities to exhibit newest technologies and solutions to increase global awareness and strengthen cooperation with overseas markets. INNOPOLIS has participated in SWITH 2024 (Singapore) with various activities: exhibiting under INNOPOLIS Pavilion, hosting INNOPOLIS Global Demoday; and attended as speakers in SWITCH at AIMX Summit 2024. Under INNOPOLIS Pavilion, 10 excellent Korea startups has exhibited their newest technologies in various fields: artificial intelligence (AI) and eco-friendly technology, biotechnology, robotic, etc. and appealed significant interest from global business partners and investors. Besides, INNOPOLIS Pavilion also marked their success at SWITCH 2024 by getting to the Final Round of SLINGSHOT pitching competition - the main event of SWITCH 2024 and a global startup competition. AgosVision, which develops a wide-field 3D vision sensor, drew attention by being selected as a TOP 50 at SLINGSHOT 2024. At the AIMX Summit 2024, INNOPOLIS held a Korean session with the theme of 'AI Briefing and Update: South Korea'. They hosted a panel talk of 4 AI experts from South Korea in various fields gathered and gave insights about current Korean AI industry and predict the future of AI. Besides, through this seminar, 4 AI experts from South Korea and also explained the support from the Government to AI industry, which is the reason why Korea AI is one of the leaders in the world. At the INNOPOLIS Global Demo Day, Edward Tay - SGTech Honoray Treasurer of SG Tech Singapore, also known as SWITCH Ambassador, has presented on the global market entry and cooperation network building of Korean companies, said, "Many VCs and buyers in Southeast Asia, including Singapore, are showing great interest in the innovative technologies and products of Korean startups". During this event, Korea companies has pitched and introduced their innovative technologies and products of startups to major investors and buyers in Southeast Asia, Korean companies has expanded global cooperation opportunities through B2B networking.
SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a decade of relentless effort — growing from weakness to strength — gradually building a vast and advanced technological system that paves a new path for drug discovery. The AI-STAL platform not only witnessed the rapid development of biotechnology, but also foreshadowed a new direction for future biopharmaceutical research. 2015: The Emergence of AI-STAL The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ultimately establishing a proprietary system with independent intellectual property rights. This process was far from smooth — our scientists delved deeply into phage display technology, rigorously screened, modified, and optimized various plasmid vectors. Through countless experiments and refinements, they successfully constructed a unique phage display plasmid vector with an unparalleled sequence. This achievement not only ensured Sanyou Bio's autonomy and independence at the technical level, but also laid a crucial foundation for subsequent breakthroughs. At the same time, Sanyou Bio demonstrated remarkable foresight in conceptual design of molecule libraries, proposing the designs for multi-pathway antigen libraries and diverse molecule libraries. At that time, the conventional approaches to antigen and molecule library construction were relatively simple and limited. Through the integration and innovation of multidisciplinary knowledge from immunology, molecular biology, and other disciplines, our research team envisioned a strategy to obtain antigens from multiple sources and built diverse molecule libraries, catering to the growing and varied needs of drug R&D. 2016: The Beginning of Commercialization In 2016, Sanyou Bio took a significant step towards commercialization. The team successfully integrated hybridoma technology with phage display technology, creating a powerful synergy. Hybridoma technology is known for producing highly specific monoclonal antibodies but suffers from issues such as low screening efficiency. In contrast, phage display technology offers high-throughput screening capabilities. By combining the strengths of both methods, Sanyou Bio's researchers developed an innovative approach: first generating preliminary specific antibodies using hybridoma technology, and then further screening and optimizing these antibodies through phage display technology, significantly improving the quality and screening efficiency of the antibodies. Based on this technology, the team also advanced the conceptual design of synthetic and semi-synthetic antibody libraries. By employing artificial synthetic and semi-synthetic approaches, the team innovatively constructed antibody libraries with increased diversity and specificity, further strengthening the company's technological portfolio. In terms of commercial applications, Sanyou Bio became a pioneer in the commercial application of mouse immune libraries in China. We brought our independently developed mouse immune library to the market, providing efficient antibody screening tools for many research institutions and pharmaceutical companies. This breakthrough quickly earned Sanyou Bio a good reputation and growing influence within the industry. 2017: The Strengthening of the Technological Foundation In 2017, Sanyou Bio focused on sharpening its technological foundation. In the conceptual design of the 100-billion-level fully human antibody library, the team conducted in-depth research on the structure and functional characteristics of fully human antibodies, integrating advanced gene synthesis and cloning technologies to envision the construction of a vast fully human antibody library at the sub-trillion level. Through extensive preliminary studies and experimental simulations, the construction strategy and technical route for the library were determined. Simultaneously, the conceptual design of the common light chain library was also carried out. Our researchers discovered that the stability and compatibility of the light chain play a crucial role in antibody performance. This led to the proposal of building a common light chain library, providing a more stable and efficient source of light chains for subsequent antibody development. Additionally, Sanyou Bio further upgraded the mouse immune antibody library. By optimizing immunization strategies and screening workflows, the affinity and specificity of antibodies within the library have been improved, significantly increasing its application value in drug R&D. 2018: The Launch of AI-STAL 1.0 2018 was a milestone year for Sanyou Bio, marking major breakthroughs in the development of the first-generation molecule library. The team successfully constructed a 100-billion-level fully human antibody library, setting a new record in the industry. The construction process faced numerous challenges, including the complexity and difficulty of gene synthesis and the low efficiency of library assembly. By optimizing gene synthesis methods and adopting high-efficiency cloning technology and screening strategies, our researchers overcame many obstacles, ultimately creating a fully human antibody library with a molecule scale several times larger than previous billion-level libraries. With the significant increase in library capacity, the number of preferred lead molecules also increased dramatically, providing a broader selection of high-quality candidate molecules for drug R&D. In the same year, Sanyou Bio also successfully built and set a record for a 10-billion-level naïve single-domain antibody library. At the time, the capacity of largest available single-domain antibody library worldwide contained only more than 4 billion. Leveraging its advanced technology platform and innovative construction strategies, Sanyou Bio broke this limitation. The team extracted single-domain antibody genes from animals such as alpacas and optimized gene cloning and expression conditions to construct a naïve single-domain library at the 10-billion level eventually. By the end of the year, Sanyou Bio had also completed the construction of a billion-level common light chain library. Throughout this process, our researchers meticulously screened and assembled light chain genes to ensure the quality and stability of the common light chain library, laying a solid foundation for the subsequent development of a trillion-level common light chain antibody library. 2019: The Development of Single-domain Antibody Library In 2019, Sanyou Bio made significant progress in the development of single-domain antibody libraries. The conceptual design of a trillion-level fully human antibody library advanced steadily. Through data analysis and technical summary of the previously constructed 100-billion-level fully human antibody library, the team proposed the idea of building a trillion-level fully human antibody library. The plan focused on further optimizing gene synthesis and library construction technologies to increase the diversity and complexity of antibodies. At the same time, Sanyou Bio successfully constructed a super 100-billion-level single-domain antibody library, once again setting a new record in the industry. To achieve this, our research team introduced innovative synthesis technologies and screening methods to improve both the quality and screening efficiency of the single-domain antibody library. In addition, the validation of the billion-level common light chain library was completed. Through a series of rigorous experimental verifications, the stability and effectiveness of the library in antibody construction were approved, providing a reliable source of light chains for antibody development in future. 2020: Deep Technological Advancements In 2020, Sanyou Bio underwent a deep technological upgrade. In the conceptual design of humanized semi-synthetic antibodies, based on their in-depth understanding of the human immune system and antibody structure, the team proposed to construct a humanized semi-synthetic antibody library through a novel combination of artificial synthesis and genetic modification. They envisioned improving the degree of humanization and reducing immunogenicity while retaining the natural activity of antibodies. Simultaneously, the conceptual design of humanized single-domain antibody library was also carried out. In view of the unique properties of single-domain antibodies, our researchers focused on humanizing the single-domain antibody framework to enhance the safety and effectiveness of the molecules for use in human body, thus constructing the humanized single-domain antibody library. Additionally, the conceptual design of the common light chain library concept was been further refined. The team conducted in-depth molecular-level research on the structure and function of common light chain, providing critical theoretical support for constructing a more efficient and optimized common light chain antibody library. 2021: Establishment of 3 Trillion-level Antibody Libraries 2021 was another milestone year for Sanyou Bio, with the successful completion of three trillion-level antibody libraries. By setting another new record in the industry, the establishment of the trillion-level fully human recombinant antibody library was a groundbreaking achievement. During the construction process, the team employed advanced gene recombination technologies and highly efficient library screening methods, ensuring exceptional antibody diversity and quality in the library. Building upon this success, the construction of the trillion-level fully human semi-synthetic antibody library was also completed. This library represented an upgraded achievement through gene recombination between CDRs based on the trillion-level fully human antibody library. Using precise gene editing techniques, our researchers optimized CDR sequences, enhancing antibody specificity and affinity. Another major breakthrough, the trillion-level humanized single-domain antibody library was also successfully established in record time. This library was built upon a highly humanized single-domain antibody framework and constructed through precise directly synthesis with reference to the characteristics of CDR sequences in nature. In same year, the screening and validation of the first trillion-level molecule library achieved outstanding results. For a single target protein, the average number of lead molecules was as high as hundreds, and the diversity was extremely high, providing abundant high-quality candidate molecules for drug R&D. 2022: The Launch of Super-trillion-level Platform In 2022, Sanyou Bio achieved new milestones in development of molecule library and platform integration. The trillion-level fully human common light chain antibi library was successfully constructed and set a record in the industry. This library effectively addressed the challenge of light and heavy chain mismatching in the construction of "Two-in-One" bispecific antibodies, providing strong support for the development of bispecific antibodies, dual-target or dual-epitope ADCs, and other antibodies. With this addition, the total capacity of Sanyou Bio's four trillion-level antibody libraries reached an unprecedented 7 trillion. On June 3, 2022, Sanyou Bio integrated the super-trillion-level molecule library and related cutting-edge technologies into a unified, comprehensive platform, named it "Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform (STAL)", and officially released it to the public. STAL was designed to integrate a variety of advanced techniques and rich molecule library resources, providing a one-stop solutions for drug R&D. Meanwhile, the construction and verification of the 100-billion-level cyclic peptide molecule library was also successfully completed. By utilizing innovative peptide synthesis techniques and advanced screening methods, our researchers developed a cyclic peptide molecule library with unique structural and functional properties, opening new frontiers for cyclic peptide drug R&D. 2023: A Giant Leap in Library Capacity In 2023, Sanyou Bio achieved a giant leap in the capacity of its super-trillion molecule library. The trillion-level peptide library was successfully constructed and set a record in the industry. The team made new breakthroughs in peptide synthesis technology and library construction methods, bringing the total capacity of the peptide library to 3 trillion. As a result, the cumulative library capacity of super-trillion molecule library exceeded 10 trillion. In October 2023, Sanyou Bio conducted a comprehensive review and official release of its Super-Trillion Innovative Biologics Discovery Platform, further refining the functions and service system. By the end of 2023, Sanyou Bio completed the construction and validation of the 100-billion-level Anti-Calin molecule library. Anti-Calin molecules possess unique structural and functional properties, offering broad application prospects in the field of targeted therapy. The successful development of such library provided a critical molecule resource for the development of related drugs. 2024: AI-driven Design In 2024, Sanyou Bio introduced AI technology to assist in the design of molecule library. The proof of concept of the second-generation super-trillion single-domain antibody library was launched first. The team used AI algorithms to analyze and predict the structure and function of single-domain antibodies and optimize the library's construction strategy. Through extensive simulation experiments and data analysis, the construction direction and key technical parameters of the second-generation super-trillion single-domain library were determined. In October 2024, the construction and verification of the second-generation super-trillion single-domain concept library was completed. At present, such second-generation single-domain library is being constructed in full swing. Simultaneously, the construction of the second-generation super-trillion peptide library is also being actively promoted. With the assistance of AI technology, the team optimized the sequence and structure of peptides to improve the quality and screening efficiency of the peptide library. In addition, the conceptual design of nucleic acid molecule library was also put on the agenda. Our researchers envisioned leveraging AI-driven design to construct nucleic acid molecule library with specific functions, paving new technical pathways for fields such as gene therapy. 2025: The Launch of AI-STAL 2.0 In January 2025, AI-STAL 2.0 was officially launched, initiating a multi-year plan to complete the construction and gradual deployment of the Intelligent 100-trillion Molecule Library. It is planned to launch 10-trillion novel single-domain library, fully integrate AI technology, optimize the gene sequence of single-domain antibodies through AI algorithms, and improve the diversity and specificity of antibodies in new molecule library. Meanwhile, AI will be integrated into the entire process of antibody discovery and optimization. From the design of antibody genes, the construction of libraries, to the screening and optimization of antibodies, AI is used throughout. Using AI algorithms in analysis and data-mining of large amount of biological data could quickly and accurately discovery potential antibody molecules, and then optimize them, greatly improving the efficiency and success rate of antibody R&D. Future Outlook Looking to the future, AI-STAL 2.0 will develop in a broader application. In terms of development direction, it explores towards 5 major directions, including indications, molecular formats, application scenarios, mini-programs, and important targets. In terms of molecular types, it covers 6 types of molecules, including fully human monoclonal antibodies, common light chain antibodies, humanized single-domain antibodies, cyclic peptide molecules, ADC molecules, and mRNA molecules, proving diversified molecular tools for the treatment of different diseases. In terms of application scenarios, it is adapted to 8 key scenarios, including ELISA, WB, IHC, IF, IP-ID, FC, SPA, and SPB. In terms of technology integration, 7 AI-driven programs are integrated, including de novo generation, epitope prediction, immunogenicity prediction, druggability prediction, specificity prediction, affinity predication, and one-click molecule design, to improve the intelligence level of R&D. In terms of disease research, it focuses on 9 major human diseases, including tumors, autoimmune, infection, metabolism, ophthalmology, neurology, cardiovascular, anti-aging, and various rare diseases. In terms of target exploration, it concentrates on in-depth research over 100K important targets to lay a solid foundation for the development of more innovative drugs. Sanyou Bio's Intelligent 100-Trillion Molecule Library (AI-STAL) has evolved from its inception in 2015 into a powerful technology platform in the field of biologics after 10 years of relentless effort and technological innovation. Moving forward, with the deep integration of AI technology and continuous expansion, AI-STAL will play an even more crucial role in tackling major human diseases, developing innovative drugs, and making outstanding contributions to human health globally. About Sanyou Bio Sanyou Biopharmaceuticals Co., Ltd. is a high-tech biopharmaceutical company with the vision of "improving the quality of human life through innovative biologics" and the mission of " to make the R&D easy for innovative biologics". The company is headquartered in Shanghai, China, with subsidiaries in the United States, Europe, and other regions. It has over 20,000 square meters of R&D and GMP facilities that are currently in operation or under planning. The company has established a world-leading preclinical intelligent and integrated R&D platform for innovative biologics, centered around an innovative platform of super-trillion antibody library. This platform accelerates the development of innovative biologics across four dimensions: new drug discovery, preclinical research, AI-assisted drug development, and frontier scientific research. Sanyou provides a comprehensive "4C" business model for innovative biologics, combining differentiated CRO, integrated CDO, collaborative CPO, and specialized CRS. The company has built a global marketing network and established business with over 1,200 pharmaceutical and biotech companies worldwide. It has completed more than 1,200 new drug discovery and development service projects, with over 50 collaborative R&D projects, including 9 that have obtained IND approval. The company has also developed thousands of RUO reagents. Sanyou has also received a number of nationwide and Shanghai recognitions and awards.
SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- Asia is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung cancer deaths worldwide(1). Many countries have applied low-dose CT scans to screen for this deadly cancer to improve early detection and treatment outcomes. However, only the highest-risk population (heavy smokers) is advised to undergo low-dose CT scans routinely to minimize the risk of radiation-induced cancer during scanning rounds(2). Moreover, CT devices are not easily accessible for many people due to geographical and economic barriers. Due to these limitations, multiple studies have pointed out surprising data: the current screening guidelines and eligibility criteria may miss over 50% of lung cancer cases in never-smokers(3); women are particularly vulnerable, with 83% of women in South-East Asia with lung cancer being never-smokers(4); non-smokers are diagnosed at a later stage than smokers (5); and about a third of lung cancer deaths occur in non-smokers(6). New screening method leveraging AI and genomics technology advantages SPOT-MAS is a blood test developed by Gene Solutions to detect multiple features of circulating tumor DNA (ctDNA) released from cancer cells, indicating if someone may have cancer. Previously, SPOT-MAS was validated as a multi-cancer early detection test in a longitudinal study involving 9,024 healthy people. While detecting multiple cancers, including lung cancer, in a single blood test is an aspirational goal, the key challenge lies in making it affordable for a large population. To address this challenge, Gene Solutions integrates a multiomics tumor ATLAS with AI-driven feature engineering and deep learning models to analyze genetic, epigenetic, and fragmentomic data. This methodology offers a precise, non-invasive, and affordable test specifically designed for lung cancer screening. Through enhanced AI analysis and the incorporation of lung-specific features, the SPOT-MAS Lung test has demonstrated remarkable effectiveness, achieving 90% sensitivity and 92% specificity(7). A new hope for lung cancer burden in Asia With extensive connections to healthcare providers across Asia, Gene Solutions aims to introduce this smart blood test to clinical practice in early 2025 to support the urgent need for accessible lung screening. In the long run, a convenient and precise test like SPOT-MAS can increase the chances of early detection for at-risk populations and potentially reduce the mortality rate associated with late diagnoses. Furthermore, ctDNA screening tests can serve as a companion tool to low-dose CT scans. In real-life practice, many CT scans yield ambiguous results, such as small lung nodules classified under LUNG-RADS (8), which might leave clinicians and patients uncertain about the malignancy status and the appropriate follow-up surveillance path. ctDNA screening results can thus support and guide diagnosis and surveillance strategies. At the January event Personalized cancer care in Asia: Advancing Genomics & AI in Singapore, Dr. Nguyen Hoai Nghia, Founder of Gene Solutions, highlighted: "This technology represents a paradigm shift in lung cancer screening, particularly for underserved populations. By harnessing the power of ctDNA and AI, we aim to make blood-based cancer screening tests more accurate and more affordable, hence support more early detection and effective treatment outcomes." Dr. Nguyen Hoai Nghia announced the performance of the SPOT-MAS Lung test at the event "Personalized Cancer Care in Asia: Advancing Genomics & AI" at SGX Auditorium, Singapore, January 2025. About Gene SolutionsGene Solutions, a pioneering biotech company in Asia, is leading the way in leveraging advanced AI and ctDNA technologies for innovative cancer detection solutions. The company partners with over 4,500 hospitals and clinics across Southeast Asia and boasts a team of approximately 250 biology experts and technicians out of a total of 700 employees. Gene Solutions has published more than 50 peer-reviewed publications and conducted over 50 multi-center studies across the region. The company, recognized for its proprietary research and CAP-accredited laboratories in Singapore and Vietnam, combines multi-dimensional genomics with AI-driven approaches to transform cancer care. For media inquiries, please contact: Gene Solutions Media Contact Ms. Emma Ngo www.genesolutions.com Email: pr@genesolutions.com References: (1) Chiu, C., & Yang, P. (2024). Challenges of lung cancer control in Asia. EClinicalMedicine, 74, 102706. doi.org/10.1016/j.eclinm.2024.102706 (2) Pozzessere, C.; von Garnier, C.; Beigelman-Aubry, C. Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned? Tomography 2023, 9, 166-177. doi.org/10.3390/tomography9010015 (3) Kerpel-Fronius, A., Tammemägi, M., Cavic, M., Henschke, C., Jiang, L., Kazerooni, E., Lee, C., Ventura, L., Yang, D., Lam, S., Huber, R. M., Yang, D., Zulueta, J., Viola, L., Mohan, A., Lee, C., Cavic, M., Schmidt, H., Kazerooni, E., . . . Huber, R. (2021). Screening for lung cancer in Individuals who Never smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee report. Journal of Thoracic Oncology, 17(1), 56–66. https://doi.org/10.1016/j.jtho.2021.07.031 (4) Barta, J. A., Powell, C. A., & Wisnivesky, J. P. (2019). Global Epidemiology of Lung Cancer. Annals of Global Health, 85(1). https://doi.org/10.5334/aogh.2419 (5) Barta JA, et al. Global Epidemiology of Lung Cancer. Annals of Global Health. (2019). 85(1): 8, 1–16. DOI: https://doi. org/10.5334/aogh.2419 (6) GLOBOCAN (2020). (7) Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma cfDNA Signatures to Enhance Lung Cancer Detection (January 11, 2025). dx.doi.org/10.2139/ssrn.5094108 (8) American College of Radiology (2022).
MELBOURNE, Australia, Feb. 5, 2025 /PRNewswire/ -- Australian medical technology company Optalert has revealed a breakthrough test for sleep issues, expanding access to sleep health technologies for millions of Australians. The simple test is conducted within 10 minutes on a smartphone, making it exceptionally accessible. It relies on a unique biomarker discovered by Optalert – as people with sleep issues often receive less oxygen as they sleep, their eyelid coordination during waking hours is impaired. Optalert's test uses the Apple iPhone's forward-facing camera to capture the subtle eyelid movements that result from this lack of coordination, using a proprietary algorithm to identify signs of sleep issues. "Optalert's new test represents a step change in expanding access to sleep health technologies," said Optalert Chief Marketing Officer Paul Zubrinich. "Our hope is that by putting accurate, accessible tools in the hands of Australians, we can make people far more aware of their sleep health, so they can enjoy a better night's rest and, in turn, a better quality of life." Optalert's algorithm was developed with data from three leading sleep laboratories: Monash Medical Centre, the Monash Biomedicine Discovery Institute, and the Institute for Breathing and Sleep (IBAS). Development involved using the algorithm to test a group of people with obstructive sleep apnoea (OSA) confirmed by polysomnography (the gold standard in OSA diagnosis) and also test a control group with no identified sleep conditions. Despite its speed and ease of use, Optalert's test achieved astonishing accuracy, with the underlying algorithm separating the groups with an accuracy of 96.6% (with a sensitivity of 84.0% and a specificity of 98.5%). Current consumer-facing tests in smartwatches rely on interpreting a user's breathing across many nights, but with only 17.3% of Australians owning a compatible device and many of those being placed on a charger overnight, these tests remain inaccessible for most. By building the test for the iPhone – a device owned by more than 50% of Australians – Optalert is making sleep health testing more accessible, while delivering greater accuracy in a shorter amount of time for the user. Approximately one in five Australians are estimated to be affected by a major sleep disorder, with conditions estimated to cost $56.5 billion each year[1] – making increased awareness of sleep health vital to the health of Australians and our economy. Quote "Wearable and app-based technologies are transforming how we approach sleep, and brain health more generally. These technologies provide continuous, personalised data that helps in identifying sleep issues, and thereby promote treatments of underlying conditions that affect the brain." – Prof. Matthew Kiernan AM,CEO Neuroscience Research Australia Enquiries For enquiries, please contact Optalert CMO Paul Zubrinich: Email: pzubrinich@optalert.com Images: Click here Owl Eye can be downloaded for Apple iPhone from the App Store at the following link:https://apps.apple.com/au/app/owl-eye-sleep-test/id6569247951?pt=118003230&ct=press-releases&mt=8 About Optalert Optalert was founded by renowned sleep researcher Dr. Murray Johns. It is the world's leading research team in the field of blepharometry, the study of eyelid movements. The firm holds multiple patents on the Johns Drowsiness Scale (JDS™), a proprietary biomarker that Harvard Medical School has deemed "commensurate with gold standard laboratory measures". It has also developed an algorithm that detects driver impairment due to intoxication. Optalert operates globally and has been commercially active in the fleet industry for over 16 years. https://www.optalert.com/ [1] Streatfeild J, Smith J, Mansfield D, Pezzullo L, Hillman D. The social and economic cost of sleep disorders. Sleep. 2021 Nov 12;44(11):zsab132. doi: 10.1093/sleep/zsab132. PMID: 34015136.
Biotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
